Immix Biopharma, Inc. Common Stock
Symbol: IMMX (NASDAQ)
2.24
▲ (7.18%) 0.150
Company Description:
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Key Stats
- Today's Open: $2.22
- Today's High: $2.808
- Today's Low: $1.907
- Today's Volume: 575.28K
- Yesterday Close: $2.09
- Yesterday High: $2.1949
- Yesterday Low: $2.07
- Yesterday Volume: 205.62K
- Last Min Volume: 30
- Last Min High: $2.24
- Last Min Low: $2.24
- Last Min VWAP: $2.24
Company Profile
- Name: Immix Biopharma, Inc. Common Stock
- Website: https://www.immixbio.com
- Listed Date: 2021-12-16
- Location: LOS ANGELES, CA
- Market Status: Active
- CIK Number: 0001873835
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $71.54M
- Round Lot: 100
- Outstanding Shares: 32.67M
- Asset Type: CS
RECENT FILINGS FOR IMMX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 3 | View |
| 2025-09-08 | 8-K | View |
| 2025-08-08 | 10-Q | View |
| 2025-06-23 | 8-K | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-03 | 424B5 | View |
| 2025-06-03 | 8-K | View |
| 2025-05-19 | ARS | View |
| 2025-05-19 | 10-Q/A | View |
Latest News on IMMX